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Background: Postthrombotic syndrome (PTS) is a common complication after iliofemoral venous thrombosis, often
resulting in poor quality of life (QOL) among the affected patients. This study assessed development of PTS and its effect
on QOL among patients treated for iliofemoral venous thrombosis by catheter-directed thrombolysis.
Methods: Patients admitted with an iliofemoral venous thrombosis and treated with catheter-directed thrombolysis at
Gentofte University Hospital from 1999 to 2008 were invited to participate. Duplex ultrasound imaging was used to
assess venous patency and valve function. Each patient completed the generic Short-Form 36-item (SF-36) health survey
assessment, producing physical component (PCS) and mental component summary (MCS) scores, and the disease-specific
Venous Insufficiency Epidemiological and Economic Study (VEINES)-Quality of Life (QOL)/Symptoms (Sym),
questionnaires to assess QOL. PTS was assessed using the Villalta scale.
Results: The study included 109 patients. Median follow-up was 71 months. PTS developed in 18 patients (16.5%) and
of those, initial thrombolysis was successful in 13. Patients with PTS had significantly worse mean  standard deviation
scores than patients without PTS on VEINES-QOL (34.2  9.6 vs 53.1  6.6; P < .0001), VEINES-Sym (34.0  8.8
vs 53.2  6.6; P < .0001), SF-36 MCS (44.2  15.5 vs 52.3  11.0; P  .005), and SF-36 PCS (42.3  9.1 vs 53.5 
7.8; P < .0001) subscales. Patients with reflux or chronic occlusions, or both, had significantly lower mean  SD scores
than patients with patent veins without reflux on VEINES-QOL (43.5  14.3 vs 51.0  8.8; P  .044) and SF-36 PCS
(47.2  10.9 vs 52.4  8.5; P  .049) scales.
Conclusion: PTS was associated with worse QOL, although only a few patients developed PTS after catheter-directed
thrombolysis of iliofemoral venous thrombosis. Patients with patent veins and sufficient valves have higher QOL scores
than patients with reflux and occluded veins. ( J Vasc Surg 2011;54:18S-25S.)
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cation after deep venous thrombosis (DVT), especially after
iliofemoral venous thrombosis. PTS is characterized by
pain and heaviness in the affected limb, and some of the
objective signs are edema, hyperpigmentation, venous ec-
tasia, and venous ulcers. Several studies have shown fre-
quencies of PTS of up to 30% to 40%, despite anticoagula-
tion therapy.1,2 In one study, the use of compression
stockings reduced the rate of PTS approximately 50% com-
pared with controls (hazard ratio for PTS in the stocking
group was 0.49).3
Previous studies have mainly focused on immediate
treatment results, complications, and recurrent thrombo-
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18Sis. Lately, focus has turned toward the effect of PTS on
uality of life (QOL), and recent research has shown that
OL among patients with PTS is poor.4,5 Standardized
nstruments assessing QOL have been developed, among
hese the Venous Insufficiency Epidemiological and
conomic Study (VEINES)-Quality of Life (QOL)/
ymptoms (Sym) questionnaire that has been evaluated
mong patients with chronic venous disease and DVT.6,7
mong patients with prior DVT, disease severity is worse
nd QOL is poorer compared with patients with other
orms of chronic venous disease.8 In 2005, Kahn et al4
eported that QOL among patients with DVT remains
oorer than population norms at 4 months and that wors-
ning of the PTS score is associated with worsening of
OL. In another study, Kahn et al9 reported that PTS has
significant impact on disease-specific QOL that may not
e captured by generic QOL measures such as the Short
orm 36-item (SF-36) health survey. Patient-reported
OL measures correlated well with physician-assessed
TS.9
These studies, however, dealt exclusively with patients
reated with anticoagulation therapy. This study inves-
igated the long-term clinical outcome among patients
ith iliofemoral venous thrombosis treated with catheter-
irected thrombolysis (CDT) to assess the development of
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tion are associated with QOL.
METHODS
This study was approved by the National Ethics Com-
mittee (journal number H-D-2007-0120), and written
informed consent was obtained from all patients before
examination.
Patients. The study population was recruited among
consecutive patients admitted with iliofemoral venous
thrombosis at the Department of Vascular Surgery,
Gentofte Hospital in Copenhagen, Denmark, and treated
with CDT between June 1999 and July 2008. After CDT,
all patients were treated with graduated compression stock-
ings class II (23-32 mm Hg) and at least 1 year of antico-
agulation therapy. Inclusion criteria were first episode of
iliofemoral DVT with an open distal popliteal vein, age
60 years, and age of thrombus of maximum 14 days.
Exclusion criteria were previous ipsilateral DVT, recent
major surgery, malignancy, or other concomitant chronic
disease, and have been described elsewhere.10
Technique. The popliteal vein was punctured under
local anesthesia, and a multiple side-hole catheter with tip
occlusion was placed in the thrombus. Infusion of tissue
plasminogen activator (t-PA) and heparin was done with
pulse-spray technique or continuously, and treatment con-
tinued until all thrombus had been resolved. Any residual
stenosis in the iliac vein was treated with stent placement.10
Follow-up. For this study, all treated patients were
invited in the period from September 2009 to March 2010
for clinical examination, including duplex ultrasound im-
aging where deep venous patency and function were as-
sessed. We only included patients with at least 1 year of
follow-up.11 All patients were asked to complete the Dan-
ish version of the generic SF-36 questionnaire and a Danish
version of the disease-specific VEINES-QOL/Sym ques-
tionnaire that was developed for this study.
Ultrasound investigation. At the clinical visit, every
patient had a thorough ultrasound examination using a
color duplex ultrasound scanner (Phillips iU22, Bothell,
Wash). Patients were supine during the scan. Venous pa-
tency of the common iliac and external iliac veins was
examined using a 5-2 MHz curved array transducer. The
common femoral vein, the femoral vein, and the popliteal
vein were scanned using a 9-3MHz linear array transducer.
Patency assessment of the veins included identification of
chronic occlusions or chronic venous disease as indicated
by the presence of old and echogenic thrombus, partial
recanalization, thickened venous wall with irregularly flow
lumen, intraluminal webs, decreased compressibility, de-
creased flow augmentation after distal compression, lack of
phasicity with respiration, and possible collateral veins.12
For assessment of deep venous valve function, patients
were scanned while standing and holding on to a support
with their weight on the contralateral leg. Reflux was
assessed in the common femoral and popliteal veins and
defined as1.0 second in the common femoral vein13 and
0.5 second in the popliteal and superficial veins.14 The superficial veins (great saphenous and small saphenous
ein) were scanned in the groin and in the popliteal fossa
nd were not examined any further if function was normal.
A standardized pneumatic cuff (Venopulse, STR,
eknik, Norway) with a cuff size of 17 cm was applied
round the calf and then rapidly inflated, followed by
eflation. This procedure was managed with a foot switch.
he cuff was inflated to 150 mm Hg and inflation was
utomatically held for 3 seconds, followed by rapid defla-
ion. A pressure of 150 mm Hg was applied because it is
nough to neutralize the hydrostatic and gravitational pres-
ures and to produce an upward blood flow. One experi-
nced investigator (RB) performed all duplex ultrasound
nvestigations.
Assessment of PTS. Recommendations for standard-
zation of PTS assessment have recently been published and
ere used in this study.11 Patients were asked not to wear
ompression stockings on the day of assessment, and most
atients were examined in the afternoon to facilitate man-
festations of symptoms and signs of PTS.11 Althoughmost
atients had been seen for follow-up annually, it was not
ossible to perform the Villalta scoring from previous visits
ecause not all of the symptoms or objective findings
eeded for PTS scoring were recorded in the chart. There-
ore, the PTS occurrence data could not be presented in a
ife table.
At the clinic visit, patients’ legs were assessed using the
illalta scale.15 The presence of five patient-rated leg symp-
oms (pain, cramps, heaviness, pruritus, and paresthesia)
nd six physician-rated clinical signs (edema, induration of
he skin, hyperpigmentation, redness, venous ectasia, and
ain during calf compression) were scored. A score of 0
none) to 3 (severe) was assigned for each item, and the
resence of a venous ulcer was recorded. A total Villalta
core of 15 or the presence of a venous ulcer indicated
evere PTS, a score of 10 to 14 represented moderate PTS,
nd a score of 5 to 9 showed development of mild PTS. A
core5means that PTS is absent. In addition, the leg with
revious DVT was classified according to the clinical com-
onent of the CEAP classification16 in one of seven clinical
lasses ranging from C0 (no evidence of venous disease) to
6 (active ulceration).
17,18
QOL assessment. Validated questionnaires in the
orm of the generic SF-3619,20 and the disease-specific
EINES-QOL/Sym6,7 were used for assessment of QOL.
he SF-36 assesses eight health concepts and produces two
ummary scores: a Physical Component Summary (PCS)
core describing physical health and a Mental Component
ummary (MCS) score describing mental health.
The VEINES-QOL/Sym consists of 26 items and in-
ludes questions about specific symptoms (heavy legs, ach-
ng legs, swelling, night cramps, heat or burning sensation,
estless legs, throbbing, itching, and tingling sensation),
imitations in daily activities, and psychologic impact, as
ell as change in the patient’s “leg problem” during the
ast year and the time of day when the leg problem is most
ntense. Two scores can be computed: the VEINES-QOL
ummary score, which assesses QOL, and the VEINES-
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Higher scores represent higher QOL. Versions of the
VEINES-QOL/Sym have been developed in English,
French, Italian, French Canadian, and recently, Norwe-
gian.21 For our patients, we developed a Danish version by
using accepted forward-backward translation methodol-
ogy.22
Statistical analysis. Mean QOL scores in patients
with and without PTS were compared. Furthermore, mean
QOL scores in patients who had patent veins without reflux
were compared with the patients who had reflux, chroni-
cally changed or occluded veins, or both. Analysis of vari-
ance was used to test the group differences while control-
ling for follow-up time and patients’ age at thrombolysis.
Because of non-normal distributions, the variables con-
cerned were transformed into ordinal rank scores before
entering the analysis.
Pearson correlation coefficient analysis was calculated
to study the association between the Villalta score and
VEINES-QOL/Sym scores. For all tests, P  .05 was
considered significant. Data were analyzed by means of
SPSS 15.0 software (SPSS Inc, Chicago, Ill) and SAS 9.1
software (SAS Institute, Cary, NC).
RESULTS
Study patients. We invited 117 patients previously
treated with CDT for acute iliofemoral venous thrombo-
sis to participate in the study. Three had experienced bilat-
eral thrombosis, resulting in 120 limbs. However, during
the time since the CDT occurred, one patient died of
cancer, four patients (including one with bilateral throm-
bosis) moved out of Denmark and were lost to follow-up,
and three patients refused to participate. This resulted in a
study cohort of 109 patients with 111 lower limbs with
previous iliofemoral DVT. Baseline characteristics of the
Table I. Baseline characteristics of patients (n  109)
Characteristic No. (%) or mean (range)
Sex
Males 24
Females 85
Age, years 31 (15-58)
Limbs with DVT
Left 86
Right 25
Iliofemoral 95
Iliac only 10
Femoral only 6
Stented limbs 62 (56)
Thrombophilia 52 (47)
Chronic occlusions not lysed 3 (2.8)
Chronic changes not lysed 2 (1.8)
Occlusion 1 week after CDT 3 (2.8)
Recurrent DVT since thrombolysis 3 (2.8)
Patients with caval atresia 8 (7)
Long-term anticoagulation 41 (38)
CDT, Catheter-directed thrombolysis; DVT, deep vein thrombosis.109 patients are presented in Table I. dMedian follow-up was 71 months (range, 15-124
onths), and at 6 years, the estimated percentage of patent
eins without reflux was 87.5% (Fig 1). On the basis of the
illalta score for each patient, the 109 patients were classi-
ed as having or not having developed PTS during the
-year period. PTS developed in 18 (16.5%); of these, 13
ad initial successful thrombolysis, but the remaining five
ad chronic changes or chronic occlusions that could not
e treated with thrombolysis. Mild PTS was diagnosed in
3 of the 18 patients and four had moderate PTS. Severe
TS developed in a patient who had been diagnosed with
n insufficient popliteal vein 1 year before this investiga-
ion. At the time of follow-up, a venous ulcer had devel-
ped and duplex ultrasound imaging demonstrated a to-
ally occluded femoral vein corresponding to a recurrent
hrombosis several months before the examination. He was
ot receiving anticoagulation therapy at the time of the
vent. Of the five patients with chronic changes or occlu-
ions, mild PTS developed in four and moderate PTS in
ne.
Of the 13 patients who developed mild PTS, seven
ere diagnosed with mild PTS because of a Villalta score of
, exclusively based on symptoms. No objective signs were
ound in these patients. The duplex ultrasound investiga-
ion showed patent deep veins without reflux, and no
uperficial reflux was detected. Two further patients in the
roup withmild PTS had symptoms from their legs because
f varicose veins and insufficiency of their great saphenous
ein, and one of those also had caval atresia. Both patients
ad patent deep veins and no deep venous insufficiency.
According to the CEAP classification, 83% were in the
roups C0 to C2 (Table II). There were 13 patients (12%)
n class C3, 6 with skin changes (C4-C6), of whom five were
n group C4. Theman with recurrent DVT, popliteal reflux,
nd a venous ulcer was in group C6.
QOL scores. Patients with PTS had significantly
ower scores on the VEINES-QOL/Sym subscales than
atients without PTS (Table III). Pearson correlation anal-
sis showed a significant correlation between the Villalta
core and VEINES-QOL (r  –0.75; P  .0001) and
EINES-Sym (r  –0.73; P  .0001; Fig 2).
The mean  standard deviation SF-36 PCS score was
2.3  9.1 in patients with PTS vs 53.5  7.8 in patients
ithout PTS (P .0001). Themean SF-36MCS score also
iffered significantly between patients with and without
TS (P  .005; Table III).
Furthermore, VEINES-QOL/Sym scores were higher
or patients with patent veins without reflux compared with
atients with reflux chronic occlusion or changes, or both,
n their deep veins; however, this only reached statistical
ignificance for the VEINES-QOL score (Table IV). A
ignificantly lower score of 47.2  10.9 was observed for
he SF-36 PCS score in patients with reflux or chronic
cclusion or changes, or both, of their veins vs 52.4  8.5
n patients with patent veins without reflux (P  .049).
owever, no association was seen between the status of the
eep veins and the MCS score (P  .674).
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lower scores on the VEINES-QOL/Sym scales were ob-
served; however, no significant difference was found (data
not shown).
DISCUSSION
In our study population of relatively young patients
without major comorbidities, PTS developed in only 16.5%
of the patients after a median follow-up of 71 months.
Furthermore, 13 of 18 patients who developed PTS had
mild PTS, and severe PTS developed in only one patient
(1% of all patients in the study). Controlling for age at
thrombolysis and follow-up time, we found PTS was asso-
ciated with worse disease-specific QOL as measured by the
VEINES-QOL/Sym questionnaire and also was associated
with worse generic QOL as measured by the SF-36 MCS
and PCS. Furthermore, we found a significant negative
correlation between PTS by means of the Villalta score and
Fig 1. Kaplan-Meier plot illustrates the estimated perce
region indicates the confidence limit.
Table II. Frequency of the different CEAP C classes
CEAP class
Patients, No.
(%)
C0 75 (68.8)
C1 5 (4.6)
C2 10 (9.2)
C3 13 (11.9)
C4 5 (4.6)
C5 0 (0)
C6 1 (0.9)
Total 109the VEINES-QOL/Sym scales. cAs demonstrated by Kahn et al,9 we also found an
ssociation between PTS and disease-specific QOL as mea-
ured by the VEINESQOL/Sym questionnaire. However,
e also found an association between PTS and generic
OL, but this was not found by generic QOL measures in
he study by Kahn et al.9 A possible explanationmay be that
he study populations had differences in thrombus location
nd differences in follow-up time.
In a recent study byGrewal et al,23 patients treated with
DT or pharmacomechanical procedures were divided in
wo groups according to their degree of clot lysis (above
nd below 50% lysis). The SF-36 mean PCS was signifi-
of patients with patent veins without reflux. The shaded
able III. Quality of life (QOL) according to patients’
ostthrombotic syndrome (PTS) status
Assessmenta
Patient PTS status
Pb
With PTS Without PTS
(n  18) (n  91)
EINES
Sym 34.0  8.8 53.2  6.6 .0001
QOL 34.2  9.6 53.1  6.6 .0001
F-36
MCS 44.2  15.5 52.3  11.0 .005
PCS 42.3  9.1 53.5  7.8 .0001
CS,Mental Component Summary score; PCS, Physical Component Sum-
ary score; SF-36, Short-Form 36; Sym, symptom; VEINES, Venous Insuf-
ciency Epidemiological and Economic Study.
Higher scores indicate better outcome. Scores are shown as mean 
tandard deviation.
Analysis of variance controlling for follow-up time and age at thrombolysis.ntageantly higher in patients with50% lysis compared with the
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Fig 2. Correlation is shown between the Villalta score and scores on the (A) Venous Insufficiency Epidemiological
and Economic Study (VEINES)-Quality of Life (QOL) and (B) Symptoms (Sym), questionnaires. The outer curves
represent 95% confidence limits. A high Villalta score represents worse postthrombotic syndrome; lower VEINES-
QOL and VEINES-Sym scores represent worse quality of life.
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tion in the United States of America, both groups of
patients treated with CDT had lower SF-36 scores, though.
Nevertheless, improved QOL was linearly correlated with
the amount of thrombus resolution.23
Because the purpose of CDT is to eliminate thrombus,
restore venous patency, and preserve venous valve function,
we compared the patients with patent veins and sufficient
valves with the group of patients with reflux or chronically
occluded or changed veins, or both. This showed higher
VEINES-QOL/Sym scores in patients with patent deep
veins without reflux; however, this only reached statistical
significance for the VEINES-QOL score. The SF-36 PCS
scores were also significantly different in these two groups;
however, no association was seen between the status of the
deep veins and the SF-36 MCS score. These results show
that the VEINES-QOL/Sym questionnaire has a better
sensitivity in capturing these vein-specific differences than
the SF-36 questionnaire.
To our knowledge, no other studies have related QOL
to vein function (patent veins without reflux). We found
positive association between vein status and the disease-
specific VEINES questionnaire.
Several studies during the last decades have shown that
PTS develops in up to almost half of the patients with DVT
treated exclusively with anticoagulation therapy.1 This rep-
resents results from patients with DVT in general and not
only those with iliofemoral thrombosis, the latter being a
group of patients having the highest risk of PTS. Further-
more, PTS develops within the first 2 years after the throm-
botic event, and about 3% of patients develop severe PTS
during that period.1 However, recent studies using CDT or
pharmacomechanical thrombolysis have shown that a more
aggressive approach in thrombus removal may reduce post-
thrombotic morbidity compared with anticoagulation
alone.10,23-26 Our results with a long-term frequency of
only 16.5% suggest that CDT is effective in reducing the
Table IV. Quality of life (QOL) according to reflux or
occlusion/chronic changes, or both, vs patent veins
without reflux
Assessmenta
Vein status
reflux and/or
occlusion/changes
(n  15)
Patent veins
without
reflux
(n  94) Pb
VEINES
Sym 44.0  13.9 51.0  9.0 .088
QOL 43.5  14.3 51.0  8.8 .044
SF-36
MCS 53.2  9.7 50.6  12.5 .674
PCS 47.2  10.9 52.4  8.5 .049
MCS,Mental Component Summary score; PCS, Physical Component Sum-
mary score; SF-36, Short-Form 36-item health survey; Sym, symptom;
VEINES, Venous Insufficiency Epidemiological and Economic Study.
aHigher scores indicate better outcome. Scores are shown as mean 
standard deviation.
bAnalysis of variance controlling for follow-up time and age at thrombolysis.incidence of PTS. pA previous study showed that the most important fac-
or with regard to prognosis after DVTwas the status of the
istal deep veins; when patent and competent, the long-
erm prognosis was good, both with regard to symptoms
nd the development of skin changes.27 Furthermore,
imbs with PTS have been found to have three times the risk
f having combined reflux and obstruction than limbs
ithout PTS.28 Labropoulos et al29 recently determined
he incidence and signs and symptoms of chronic venous
isease and recurrent thrombosis in relation to the location
nd extent of the initial thrombus. Recurrent thrombosis
nd skin damage was more likely to develop in patients with
ultiple sites of thrombosis than in patients with thrombo-
is in a single vein segment. Patients with reflux and ob-
truction presented more skin damage than those with
eflux or obstruction alone.
We only found six patients in the CEAP groups C4 to
6 after a median follow-up of almost 6 years, even though
ll patients had had an iliofemoral venous thrombosis. A
ecent study evaluating the clinical progression of CEAP
lasses in patients with DVT treated exclusively with anti-
oagulation30 found that skin damage was documented in
% after 1 year and had increased to 25% of the patients at
years. A change in clinical class was seen in 30% of
ostthrombotic limbs from years 1 to 5, and the most
mportant predictor of progression was ipsilateral recurrent
hrombosis.30
As mentioned, seven study patients were characterized
s having mild PTS, a diagnosis exclusively based on symp-
oms. All of these patients had patent deep veins without
eflux. However, it is important to recognize that PTS
roduces a range of symptoms and signs and that the
iagnosis of PTS should be determined from both symp-
oms and clinical signs.18
Our study has some limitations. Although data were
rospectively collected, there was no control group of
atients with iliofemoral venous thrombosis treated with
nticoagulation alone. Because our patients were relatively
oung and healthy, no comorbid conditions were recorded,
or was body mass index, which has been described to
egatively influence outcome. Because patients were seen
s part of a yearly routine investigation and invited to
articipate in this study, the ultrasound investigations were
ot blinded.
Some patients in the study may have been misclassified
ecause the diagnosis of PTS was derived from symptoms
nd clinical signs and no single objective test exists to
iagnose the condition. However, all patients were ass-
ssed using four different validated instruments (SF-36,
EINES, CEAP, and Villalta) and our median follow-up
as 71 months (range, 15-124 months).
The small number of patients with PTS is a limitation,
nd even though we controlled the analysis for potential
onfounding from age and follow-up time, other nonmea-
ured confounding might have played a role.
Another limitation of our study might be that our
anish version of the VEINES questionnaire has not been
sychometrically validated. However, we performed the
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found a strong and significant correlation between PTS and
VEINES-QOL/Sym, respectively.
One experienced ultrasound investigator performed all
ultrasound examinations, which might be a limitation.
However, in case of any doubt about the findings, patients
were scanned again by another experienced investigator.
Because we included all consecutive patients in this
study, we also included eight patients with atresia of the
inferior vena cava treated with CDT. The results concern-
ing reflux and patency in these patients did not differ from
the main group.31
CONCLUSIONS
This study emphasizes that CDT of iliofemoral venous
thrombosis is effective in preserving venous patency and
venous valve function and that patients with patent deep
veins and sufficient valves have higher QOL scores than
patients with reflux and occluded veins. Furthermore, al-
though the incidence was low, PTS was associated with
worse QOL in patients with iliofemoral venous thrombosis
treated with CDT.
We thank Charlotte Strandberg and Christina Kin-
nander at the Department of Radiology, Gentofte Hospi-
tal, for assisting with ultrasound investigations of some
patients, and Maria Stage for her help in data analysis.
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